Australia is anticipating the arrival of Retatrutide, a novel medication from Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates impressive results in research studies, implying a https://bookmarkbells.com/story22049094/this-new-drug-retatrutide-australia-a-promising-hope-for-obesity-treatment